Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes.

In 30 seconds

This post hoc exploratory analysis of two randomized, placebo-controlled phase 2 trials examined fasting plasma metabolite and lipid changes with retatrutide in participants with obesity, with or without type 2 diabetes. Higher doses were associated with sustained changes in metabolites linked to fatty acid oxidation and insulin resistance. Mediation analyses suggested that changes in the fatty-acid-oxidation biomarker cluster accounted for 23.2% of weight reduction in participants without diabetes, compared with 12.7% in those with diabetes. The authors interpreted the metabolic changes as being in a direction associated with improved metabolic health and reduced cardiovascular risk.

Key findings

• Changes in 3-hydroxybutyrate, acetylcarnitine, free carnitine, and long-chain acylcarnitines were associated with higher retatrutide doses in both populations.
• Mediation analyses suggested this biomarker cluster mediated 23.2% of weight reduction without type 2 diabetes and 12.7% with type 2 diabetes.
• Changes in branched-chain amino acids and catabolic products, 2-aminoadipic acid, 2-hydroxybutyrate, urate, and triglycerides were sustained across study endpoints.

Why it matters

The findings provide a metabolic profile associated with retatrutide treatment beyond changes in weight and glycaemia. They suggest that fatty acid oxidation and insulin-resistance-related pathways may respond in both populations, while the estimated contribution of the measured fatty-acid-oxidation biomarkers to weight reduction differed by diabetes status. These exploratory associations may help frame further investigation of metabolic effects.

What to keep in mind

This was a post hoc exploratory analysis of phase 2 trials; the reported biomarker mediation does not establish that these metabolic changes caused weight reduction or reduced cardiovascular risk.